Free Trial
→ A Simple Guide to Options Trading While It's Still Free (From True Market Insiders) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$96.96
$99.17
$79.52
▼
$124.00
$24.52B1.25901,220 shs1.32 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$37.07
$33.61
$23.62
▼
$40.17
$23.13B0.813.94 million shs2.33 million shs
Incyte Corporation stock logo
INCY
Incyte
$112.79
$122.76
$82.82
▼
$132.60
$22.86B0.741.73 million shs1.12 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$14.62
$9.25
$1.76
▼
$15.30
$6.62B0.7619.66 million shs16.97 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.06%+0.24%+7.65%-5.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+6.68%+14.17%+28.72%+16.54%
Incyte Corporation stock logo
INCY
Incyte
0.00%-2.18%-7.15%-1.26%+34.59%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%+2.81%+70.00%+261.88%+596.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$96.96
$99.17
$79.52
▼
$124.00
$24.52B1.25901,220 shs1.32 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$37.07
$33.61
$23.62
▼
$40.17
$23.13B0.813.94 million shs2.33 million shs
Incyte Corporation stock logo
INCY
Incyte
$112.79
$122.76
$82.82
▼
$132.60
$22.86B0.741.73 million shs1.12 million shs
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$14.62
$9.25
$1.76
▼
$15.30
$6.62B0.7619.66 million shs16.97 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.06%+0.24%+7.65%-5.00%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.00%+6.68%+14.17%+28.72%+16.54%
Incyte Corporation stock logo
INCY
Incyte
0.00%-2.18%-7.15%-1.26%+34.59%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
0.00%+2.81%+70.00%+261.88%+596.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.65
Moderate Buy$125.6929.63% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$42.5014.65% Upside
Incyte Corporation stock logo
INCY
Incyte
2.52
Moderate Buy$127.7013.22% Upside
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
2.62
Moderate Buy$12.90-11.76% Downside

Current Analyst Ratings Breakdown

Latest IOVA, BNTX, GMAB, and INCY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2026
Incyte Corporation stock logo
INCY
Incyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeBuy (B) ➝ Buy (B+)
10/8/2026
Incyte Corporation stock logo
INCY
Incyte
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetSector Perform$109.00 ➝ $114.00
10/8/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Argus logo
Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHold
10/8/2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$6.00 ➝ $11.00
10/7/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$115.00 ➝ $114.00
10/7/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $45.00
10/7/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $50.00
10/5/2026
Incyte Corporation stock logo
INCY
Incyte
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$127.00
10/5/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$45.00 ➝ $54.00
10/5/2026
Incyte Corporation stock logo
INCY
Incyte
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$145.00 ➝ $157.00
10/2/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 10/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.55$1.34 per share72.62$96.59 per share1.00
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B6.22$1.61 per share23.03$9.10 per share4.07
Incyte Corporation stock logo
INCY
Incyte
$5.14B4.45$6.18 per share18.25$26.32 per share4.29
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
$324.97M20.38N/AN/A$1.76 per share8.31
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$7.83N/AN/AN/A-63.54%-6.86%-6.00%11/3/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2729.1923.021.7219.08%14.89%7.73%11/5/2026 (Estimated)
Incyte Corporation stock logo
INCY
Incyte
$1.29B$7.8514.3714.803.6027.71%29.93%22.88%10/29/2026 (Estimated)
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$390.98M-$0.73N/AN/AN/A-89.11%-40.51%-31.65%11/5/2026 (Estimated)

Latest IOVA, BNTX, GMAB, and INCY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37N/AN/AN/A$1.20 billionN/A
11/5/2026Q3 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.0861N/AN/AN/A$114.44 millionN/A
11/3/2026Q3 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$0.8480N/AN/AN/A$1.20 billionN/A
10/29/2026Q3 2026
Incyte Corporation stock logo
INCY
Incyte
-$3.20N/AN/AN/A$1.47 billionN/A
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
8/6/2026Q2 2026
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
-$0.1335-$0.11+$0.0235-$0.11$87.83 million$99.31 million
8/4/2026Q2 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.3983-$2.5340-$0.1357-$3.70$180.18 million$122.31 million
7/28/2026Q2 2026
Incyte Corporation stock logo
INCY
Incyte
$2.15$3.09+$0.94$2.81$1.50 billion$1.67 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Incyte Corporation stock logo
INCY
Incyte
N/AN/AN/AN/AN/A
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
7.85
7.80
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Incyte Corporation stock logo
INCY
Incyte
N/A
4.59
4.51
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
N/A
4.34
3.82

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Incyte Corporation stock logo
INCY
Incyte
96.97%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
77.03%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Incyte Corporation stock logo
INCY
Incyte
16.20%
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
7.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029624.06 million614.45 millionOptionable
Incyte Corporation stock logo
INCY
Incyte
2,844202.70 million169.86 millionOptionable
Iovance Biotherapeutics, Inc. stock logo
IOVA
Iovance Biotherapeutics
975452.97 million417.64 millionOptionable

Recent News About These Companies

Iovance Biotherapeutics (NASDAQ:IOVA) Shares Climb 6.6% After Analyst Upgrade
October 11 at 1:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106783
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Expected to Rise, Robert W. Baird Analyst Says
October 10 at 2:18 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31104739
Iovance Expands Lifileucel Into Sarcoma: What SARATOGA Means for Investors
October 9 at 12:51 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/iovance-expands-lifileucel-into-sarcoma-what-saratoga-means-for-investors?utm_source=marketbeat.com&utm_medium=referral
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 6.6% on Analyst Upgrade
October 9 at 10:19 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-iovance-biotherapeutics-nasdaq-iova-shares-up-66-on-analyst-upgrade-2026-10-09/
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Gets Price Target Increase from Robert W. Baird
October 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-iovance-biotherapeutics-nasdaq-iova-stock-gets-price-target-increase-from-robert-w-baird-2026-10-08/
AVBCC Recognizes Iovance Biotherapeutics’ Dr. Fred Vogt with Inaugural Global Cancer Research & Innovation Award
October 7, 2026  |  greenbaypressgazette.comG
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 6.2% - Here's Why
October 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-iovance-biotherapeutics-nasdaq-iova-stock-price-down-62-heres-why-2026-10-06/
Iovance: Buy Now Before Many Growth Catalysts Kick In
October 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4951924-iovance-buy-now-before-many-growth-catalysts-kick-in
Why Iovance Biotherapeutics (IOVA) Effortlessly Soared 256% in Q3
October 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-iovance-biotherapeutics-iova-effortlessly-045604567.html
Iovance Biotherapeutics (IOVA) Stock Gets Fair Value Boost On Amtagvi Demand And Margin Outlook
October 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/iovance-biotherapeutics-iova-stock-gets-210751395.html
Why Is Iovance Biotherapeutics (NASDAQ:IOVA) Suddenly a Must-Watch Healthcare Stocks Name?
October 2, 2026  |  kalkinemedia.comK
Iovance Biotherapeutics consensus price target increased by 34.74% to $13.06
October 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/iovance-biotherapeutics-consensus-price-target-increased-by-34-74-to-13-06/ar-AA2dpkOd
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
October 2, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2999321/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_earnings_esp-2999321
What is Zacks Research's Forecast for IOVA FY2026 Earnings?
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-zacks-researchs-forecast-for-iova-fy2026-earnings-2026-10-02/
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Gets Price Target Increase from Wells Fargo & Company
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077037
Iovance Biotherapeutics Names Noah Berkowitz CMO
October 1, 2026  |  rttnews.comhttps://www.rttnews.com/3695783/iovance-biotherapeutics-names-noah-berkowitz-cmo.aspx
IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
October 1, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/iova-stock-hits-over-2-141513877.html
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372718/0/en/iovance-biotherapeutics-appoints-noah-berkowitz-m-d-ph-d-as-chief-medical-officer.html
HC Wainwright Brokers Increase Earnings Estimates for IOVA
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31073650
HC Wainwright Brokers Boost Earnings Estimates for IOVA
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-brokers-boost-earnings-estimates-for-iova-2026-10-01/
HC Wainwright Forecasts Strong Price Appreciation for Iovance Biotherapeutics (NASDAQ:IOVA) Stock
October 1, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31072066

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNTech stock logo

BioNTech NASDAQ:BNTX

$96.96 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$96.89 -0.07 (-0.07%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$37.07 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$37.06 -0.01 (-0.03%)
As of 10/9/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Incyte stock logo

Incyte NASDAQ:INCY

$112.79 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$113.30 +0.50 (+0.45%)
As of 10/9/2026 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Iovance Biotherapeutics stock logo

Iovance Biotherapeutics NASDAQ:IOVA

$14.62 0.00 (0.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$14.61 -0.01 (-0.08%)
As of 10/9/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas